1. The excretion of 2,4-dimethyl-6-sulphanilamidopyrimidine (sulphasomidine; Elkosin) and 4-methoxy-2-methyl-6-sulphanilamidopyrimidine (sulphamethomidine) given orallywas examined in man, rhesus monkey, rabbit and rat. 2. About 70% of sulphasomidine (0.1g./kg.) is excreted mainly unchanged in the urine by these species in 24hr.; less than 15% of the dose is acetylated and there is no marked species difference in the fate of this drug. 3. Sulphamethomidine is excreted more slowly than sulphasomidine, and in the rat, rabbit and monkey the main metabolite is the N4-acetyl derivative. In man, only 20-30% of the dose is excreted in 24hr.
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and nearly 70% of this is sulphamethomidine Nl-glucuronide, which is also excreted by the monkey but not by the rat or rabbit. There is therefore a marked species difference in the metabolism of sulphamethomidine. 4. Sulphamethomidine Nl-glucuronide was synthesized and shown to be identical with the glucuronide isolated from monkey urine. 5. Sulphasomidine, sulphamethomidine and sulphadimethoxine (2,4-dimethoxy-6-sulphanilamidopyrimidine) were acetylated by rabbit or monkey liver homogenates. Although sulphasomidine is poorly acetylated in vivo, it is acetylated in vitro at rates comparable with those of the other two drugs. 6. The solubilities, partition coefficients and plasma-protein-binding of the drugs were measured. 7. The results are discussed.
The long-acting sulphonamide drug sulphadimethoxine (2,4-dimethoxy-6-sulphanilamidopyrimidine) shows a remarkable species difference in metabolism (Bridges, Kibby, Walker & Williams, 1968) in that it is excreted in man and other primates, but not in several lower species, mainly as an Nl-glucuronide (Adamson, Bridges & Wiiams, 1966) . It was shown that this formation of an Nl-glucuronide did not occur in man and the rhesus monkey if the positions of the methoxy groups were altered, for 2-, 4-or 5-methoxy-and 2,5-or 4,5-dimethoxy-6-sulphanilamidopyrimidines did notform appreciable amounts of Nl-glucuronide (Bridges, Kibby, Walker & Williams, 1969) . It appeared therefore that formation of Nl-glucuronide was associated with the 2,4-disubstitution ofthe pyrimidine ring in this series of drugs. Two other drugs of this series containing 2,4-disubstituted pyrimidine rings have now been examined in man, monkey, rat and rabbit. These are 2,4-dimethyl-6-sulphanilamidopyrimidine (sulphasomidine; Elkosin), a short-acting antibacterial agent, and 4-methoxy-2-methyl-6-sulphanilamidopyrimidine (sulphamethomidine), a medium-long-acting drug in man (Cooper, Madoff & Weinstein, 1962 and rapidly excreted mainly as the unchanged drug, the extent of acetylation being low (5-15% of the dose) (Prior & Saslow, 1951) . The excretion of a glucuronide of sulphasomidine has been claimed (Walter, 1960) . Sulphamethomidine is well absorbed in the rabbit and dog, but poorly so in the rat. It is excreted mainly as the acetyl derivative in the rabbit and rat (DiCarlo, Malament, Haynes & Phillips, 1962) . In man, about 26% of an oral dose is excreted in the urine in 24hr., mainly as a glucuronide, which is claimed to be a conjugate of a hydroxysulphamethomidine in which the hydroxyl group occurs in the pyrimidine ring (DiCarlo, Malament & Phillips, 1963) . We have reported briefly (Bridges, Walker & Williams, 1967 ) that this glucuronide is an Nl-glucuronide similar to that formed in man from sulphadimethoxine (Bridges, Kibby & Williams, 1965) . Sulphasomidine, on the other hand, does not form this type of glucuronide. In the present paper an attempt is made to relate these findings to the physical properties of these drugs.
MATERIALS AND METHODS
Elkosin), m.p. 240-241°, 2,4-dimethoxy-6-sulphanilamidopyrimidine (sulphadimethoxine; Madribon), m.p. [4] [5] [6] [7] [8] [9] ; N, 9-2; S, 5.2%). The above ester (1g.) in methanol (25ml.) was treated with 0-5N-barium methoxide in methanol (2.5ml.) and the mixture kept for 3 days at 00. Then and water (12.5ml.) were added, and the solution was passed through a column (2.5 cm. x 10 cm.) of Amberlite CG-120 (H+ form; 100-200 mesh) (British Drug Houses Ltd., Poole, Dorset). The column was washed with water (10ml.) and then eluted with 2N-ammonia (75ml.) and finally water (50ml.). The combined eluates were evaporated at 450 in vacuo to a white solid. This was dissolved in methanol (5 ml.) and the solution banded on a thin-layer plate of fluorescent silica gel, which was irrigated with propan-1-ol-aq.ammonia (sp.gr. 0-88) (7:3 v/v) for 3hr. The band corresponding to sulphamethomidine Nl-glucuronide was eluted with 0-2N-ammonia and the eluate evaporated to dryness at 450 in vacuo. This process was repeated and the ammonium 1-deoxy-l-[Nl-(4-methoxy-2-methylpyrimidin-6-yl)8ulphanil-amidogluco8id]uronate was recrystallized from methanol to give white needles, m.p. 140-1500 (decomp.) and [x]20D + 4.00 (c5 in water) (Found: C, 42-5; H, 5-1; N, 13-8; 5, 6-6; C18H25N509S,H20 requires C, 42-8; H, 5-3; N, 13-9; S, 6-3%).
N4-Acetylsulphamethomidine, m.p.218-220°, from 25%
(v/v) acetic acid, and N4-acetylsulphasomidine, m.p. 2950, by precipitation from dimethyl sulphoxide solution with water, were prepared by standard methods with acetic acid and acetic anhydride. Sulphamethomidine N4-glucuronide. Sulphamethomidine (11g.) in dimethylformamide (lOml.) was added to a solution of sodium glucuronate (0-6g.) in ethylene glycol (20ml.). The mixture was heated for 10min. at 700 and then kept in the dark for 24hr. at room temperature. On addition of excess of acetone a gel formed, so sufficient water to just dissolve the gel was added. The solution was then kept for several days at room temperature and white crystals, m.p. 156-157°, of the sodium salt of sulphamethomidine N4-glucuronide separated. The compound, which readily reduced Benedict's solution and Fehling's solution on warming, was very labile and was not obtained entirely free of sulphamethomidine. It could, however, be used for chromatographic purposes (see Table 1 ) and was easily distinguishable from sulphamethomidine NI-glucuronide on paper.
Sulphasomidine N4-glucuronide and the N4-sulphates of sulphamethomidine and sulphasomidine were prepared by the methods of Bridges et at. (1968 Bridges et at. ( , 1969 . They were difficult to purify, but could be used to determine their Rp values (see Table 1 ).
Chromatography. The Rp values and colour reactions of sulphamethomidine and sulphasomidine and their derivatives are shown in Table 1 .
Spectra. The Perkin-Elmer Infracord and Unicam SP. 500 spectrophotometers were used.
Quantitative method8. Free and total amines in urine and bile and metabolites separated on paper chromatograms were estimated essentially as described by Bridges et al. (1968) .
Animate. Wistar albino rats (Porton strain), New Zealand white rabbits and rhesus monkeys were used. The drugs were given orally. Monkeys received the powdered drugs concealed in honey, rabbits received them by stomach tube suspended in water made slightly alkaline with NaHCO3 and containing a little bile salt, and rats received them by stomach tube suspended in aq.0-5% CM-cellulose (1 ml.). Human subjects took the powdered drug in rice-paper sachets. The bile ducts of rats were cannulated as described by Abou-El-Makarem, .
I8otation ofmetabolite8. (a) N4-Acetylsulphamethomidine. The 24hr. urine (185ml.) of a rabbit (5kg.) that had received sulphamethomidine (0-5g.) was brought to pH5-5 with N-HCI and then shaken with ethyl acetate (400ml.). The extract was evaporated at 450 to a paste, which was then dissolved in m-Na2CO3 (lOml.). The solution was treated with 2 N-HCI (lOml.) and the solid that formed was collected and dissolved in a little aqueous ethanol. The solution was banded on a thin-layer plate (fluorescent silica gel) and developed for 3hr. in solvent B (Table 1 ). The area containing the N4-acetyl compound was located and the metabolite extracted with 0-2N-ammonia. The extract was evaporated at 450 in vacuo and the N4-acetylsulphamethomidine (45mg.) had m.p. and mixed m.p. 218-220o after recrystallization from 25% acetic acid. It was characterized by Rp values and i.r. spectrum.
(b) Sulphamethomidine Nl-glucuronide. The 24hr. urine (300ml.) of a monkey given the drug (0-5g.) was concentrated to 50ml. in a rotary evaporator at 450 in vacuo. Ethanol (50ml.) containing 2N-ammonia (5%, v/v) was added and the solution, filtered from solid material, was freeze-dried. The residue in a little aqueous ethanol was banded on Whatman 3MM paper and chromatographed in solvent B (Table 1) Whatman no. 1 paper was used. The solvents (descending) were: A, butan-l-ol-aq. ammonia (sp.gr. 0.88)-water (10:1 :1, by vol.); B, propan-l-ol-aq.ammonia (sp.gr.088) (7:3, v/v); C, butan-l-ol-water-acetic acid (4:2:1, by vol.), run for 12 hr. DMAC, p-Dimethylaminocinnamaldehyde; NR, naphtharesorcinol spray (see Bridges et al. 1965 Hydroly8is of 8ulphamethomidine and it8 metabolite8. The drug or its N4-acetyl derivative (0 5g.) dissolved in ethanol (5 ml.) was mixed with 2N-HC1 (5 ml.) and heated at 1000 for lhr. The residual solution (2ml.) was placed as a band (10cm.) on Whatman 3MM paper and chromatographed with solvent A, B or C (Table 1) . Three main products were detected, namely sulphamethomidine, sulphanilic acid and an unknown suspected to contain the pyrimidine moiety. The areas corresponding to sulphanilic acid and the unknown were eluted with 2N-ammonia. The eluates were evaporated to dryness at 450 in vacuo and i.r. spectra of the residues examined. The sulphanilic acid residue, m.p. 2880 (decomp.), was identified but not the unknown.
Aqueous solutions of biosynthetic or synthetic sulphamethomidine N1-glucuronide (lmg./ml.) were heated with an equal volume of 2N-HCl at 1000 for 1 hr. The hydrolysates were then chromatographed as above and the products identified by Rp values and colour reactions.
An aqueous solution (0-8ml.) of the ammonium salt of synthetic sulphamethomidine N'-glucuronide (1 mg./ml.) free of sulphamethomidine (by chromatography) was added to each ofthree tubes. To one tube was added 1000 Fishman units (Fishman & Barnfeld, 1955) of ,B-glucuronidase (Ketodase; William R. Warner and Co., Morris Plains, N.J., U.S.A.) in sodium acetate buffer, pH5 (0-2ml.) To the second was added the same amount of boiled enzyme and to the third 0*2ml. of water. The tubes were plugged and incubated for 24hr. at 37°. The contents of the tubes were then chromatographed in solvents A, B and C (Table 1) . The experiment was repeated with the biosynthetic glucuronide, pKa, solubility and partition coefficient8. These were determined as described in the preceding paper (Bridges et al. 1969 ). Acetylation by liver homogenate8. The rates of acetylation of the drugs by liver homogenates were measured as described by Bridges et al. (1969) .
Protein-binding. Fresh human blood (40ml.) mixed with heparin (0-4ml. or 2000 units; Weddel Pharmaceuticals, London, E.C. 1.) was centrifuged at 2000g for 10min. The sulphonamide drug (2.4mg.) was dissolved in the plasma (20ml.) and 4 ml. of 0-1m-citrate-0-2M-Na2HPO4 buffer, pH7-4, added. The resulting solution (5ml.) was placed in a bag made ofcellophan tube tied at both ends (15 cm. x 3 cm. flat width). The bag was placed with a flat surface against a sintered-glass disk (20mm. diam.; porosity 1; Pyrex Co., Sunderland) near the bottom of a polythene centrifuge tube (10cm. x 2-7cm.). The tube was centrifuged at 3000g for 2hr. at 18°. The contents of the bag were analysed for total drug (bound and unbound) by adding 20% (w/v) trichloroacetic acid (1 ml.) to the plasma (1 ml.), then centrifuging at 2000g for 5min. and analysing the supernatant by the Bratton & Marshall (1939) 
RESULTS AND DISCUSSION
The excretion of total amine after the administration of 2,4-dimethyl-6-sulphanilamidopyrimidine 175 1 (sulphasomidine) and 4-methoxy-2-methyl-6-sulphanilamidopyrimidine (sulphamethomidine) is shown in Table 2 . In the four species studied, sulphasomidine and its metabolites are more rapidly excreted in the urine than are those of sulphamethomidine, since about 70% of the former is excreted in 24 hr. and about 80% in 2 days, whereas with the latter drug the 24 hr. excretion is 20-30% in man, 40-50% in the rat, 50-60% in the monkey, but nearly 70% in the rabbit. The nature of the metabolites of the two drugs in urine is shown in Table 3 . Sulphasomidine is largely excreted unchanged in the four species, for more than 70% of the 24 hr. excretion is unchanged drug and less than 20% is N4-acetylated, the other metabolites, i.e. N4-sulphate and N4-glucuronide, being of little or no importance. With sulphamethomidine, however, the proportion of unchanged drug excreted is less than 20% of the 24 hr. excretion and the major metabolite in the rat, rabbit and monkey is N4-acetylsulphamethomidine (60-80% of the 24 hr. excretion). However, in man the acetyl derivative is relatively minor (16%) and the major metabolite is now the Nl-glucuronide (68% of the 24 hr. excretion). This glucuronide is also an important metabolite in the monkey (32%), but it is quantitatively less than the N4-acetyl compound (59%).-In the rabbit and rat, no N'-glucuronide was detected in the urine. Small amounts of the N4-sulphate of sulphamethomidine were found in rat, monkey and human urine.
It appears that, in the four species studied, there is nIo marked difference in the metabolism and excrstion of sulphasomidine (I; R2 = R4= CHO) and, aJthough this drug is substituted with methyl groups in the 2-and 4-positions of the pyrimidine ring, there is no formation of Nl-glucuronide in man and the monkey as with sulphadimethoxine (I; R2 = R4= 0 CICHO), which has methoxyl groups in these positions (Bridges et al. 1968 The metabolites of sulphasomidine (SS) and sulphamethomidine (SM) were separated chromatographically and determined as described in the text. The urine collected during the first 24 hr. after dosing was analysed and the amount of each metabolite is expressed as a percentage of the amount excreted in 24 hr. The amount excreted in 24 hr.' is given in t See Table 1 . Solvents B and C were also used to confirm the identifications. t The unknown spot is probably that of the pyrimidine moiety which showed up on paper as a dark spot in u.v. light. Table 5 . Acetylation of 8ulpha8omidine and related drug8 by liver homogenate8
The incubation mixture consisted of 0-31M-drug in lml. of 0-1 M-citrate-0-2M-Na2HPO4 buffer, pH7-4, and the 2000g supernatant of liver homogenate equivalent to 330mg. of liver in 1 ml. of 0-25M-sucrose (see the text). Averages for three animals are gi ven with ranges in parentheses. with sulphamethomidine (I; R2 = CH3, R4 = O * CH3), which has a methyl group in position 2 and a methoxyl group in position 4, a marked species difference again appears, for Nl-glucuronide formation occurs in man and the monkey but not in the rat and rabbit. With 2-methoxy-6-sulphanilamidopyrimidine (I; R2=0.CH3, R4=H) and sulphamonomethoxine (I; R2 = H, R4 = 0.CH3), in which one methoxyl group occurs in the 2-or the 4-position respectively, formation of Nl-glucuronide does not occur (Bridges et al. 1969) .
Sulphamethomidine Nl-glucuronide is slowly hydrolysed by ,B-glucuronidase to sulphamethomidine and glucuronic acid (Table 4 ) and by Nhydrochloric acid to sulphanilic acid, glucuronic acid and an unidentified pyrimidine derivative. Its infrared spectrum shows an SO2 stretching frequency at 1160cm.-1 and therefore, by using the same arguments as Bridges et al. (1965) for sulphadimethoxine N1-glucuronide, it is suggested that the glucuronic acid residue in the sulphamethomidine glucuronide formed in man and the monkey is attached to the sulphonamide nitrogen atom. The 2-and 3-hydroxysulphanilic acids (see Table 1) were not found as acid-hydrolysis products, and ,B-glucuronidase converted the glucuronide into sulphamethomidine, and therefore it is concluded that the glucuronide was not an O-glucuronide of a hydroxy-sulphamethomidine in which the hydroxyl group is somewhere in the pyrimidine moiety (cf. DiCarlo et al. 1963 ). The glucuronide is easily distinguishable from the unstable and reducing N4-glucuronide (see Table 1 ).
Biliary excretion. The biliary excretion of sulphasomidine and sulphamethomidine and their acetyl derivatives was examined in rats. The compounds were injected intraperitoneally into biliarycannulated rats at a dose of lOOmg./kg. With sulphasomidine (mol.wt. 278) 6.5%, appeared in the bile in 24 hr. (2.1% free and 4-4% acetylated); whereas with N4-acetylsulphasomidine (mol.wt. 320) 4.6% appeared in the bile unchanged. With Table 6 . pKa, 8olubility and di8tribution coefficient8 of some sulphonamide drugs Solubility was determined in O lm-citrate0-2 M-Na2HPO4 buffer, pH7-4. Partition coefficients were between chloroform and the same buffer. pKa values were determined as described by Krebs & Speakman (1945 sulphamethomidine (mol.wt. 294) 6-5% also appeared in the bile in 24 hr., made up of 1-3% of unchanged drug, 3.3% of N4-acetyl derivative, 0.3% of N4-glucuronide and 1.6% of Nl-glucuronide. Thus in the rat, although no Nl-glucuronide appears in the urine, a small amount is formed and excreted in the bile. N4-Acetylsulphamethomidine (mol.wt. 336) appeared in the bile to the extent of 4% of the dose as the unchanged compound. The values given for the biliary excretion of these compounds are averages for three animals. The biliary excretion of these compounds in the rat is of a low order, and this would have been expected on the hypotheses put forward by on polarity and molecular weight and the extent of biliary excretion.
Acetylation. Sulphasomidine is poorly acetylated in vivo whereas sulphamethomidine is well acetylated in the rat, rabbit and monkey (Table 3) . However, in vitro sulphasomidine is acetylated in rabbit or monkey liver homogenates at a rate not very different from that of sulphamethomidine or sulphadimethoxine (see Table 5 ). It would appear that in vivo sulphasomidine may be excreted at a rate that does not allow extensive acetylation. At pH 7-4, sulphasomidine is twice as soluble as sulphamethomidine and nearly five times as soluble as sulphadimethoxine (see Table 6 ) in phosphate buffer, whereas its distribution coefficient (chloroform/ buffer, pH 7 4) is only 15% of that of sulphamethomidine and about 3% of that of sulphadimethoxine (Table 6 ). Sulphasomidine is thus more watersoluble and less lipid-soluble at pH 7-4 than the other two drugs, and therefore would have less tendency to be reabsorbed by the renal tubules, whereas the other two would be more readily reabsorbed and undergo further metabolism. The N4-acetyl derivatives of the three drugs are relatively poorly lipid-soluble and would tend to be excreted once formed.
The extent of the binding of the drugs and some of their metabolites to human plasma proteins in vitro is shown in Table 7 . Compared with sulphamethomidine (90%) and sulphadimethoxine (90%), sulphasomidine (66%) is less bound to protein and this suggests that more is immediately available for excretion by the kidney. It is to be noted that the Nl-glucuronides are poorly bound whereas the N4-acetyl derivatives are relatively highly bound.
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